Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHDYBN)

• Drug Name: RS-102,221 Drug Info
• Synonyms: RS-102221; RS102221; 185376-97-0; RS 102221 HCl; Tocris-1050; RS-102,221; Biomol-NT_000133; AC1MW45U; GTPL187; CHEMBL88402; SCHEMBL7107338; BPBio1_000243; RS102221 HCl; CHEBI:93519; BDBM85098; HZZZZODVDSHQRG-UHFFFAOYSA-N; BCP03496; ZINC26580328; PDSP1_001633; PDSP2_001617; NCGC00024967-02; NCGC00024967-01; L000523; BRD-K87048468-003-01-9; N-{5-[5-(2,4-dioxo -1,3,8-triazaspiro[4.5]dec-8-yl)pentanoyl]-2,4-dimethoxyphenyl}-4-trifluoromethylbenzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 3693566
  ChEBI ID: CHEBI:93519
  CAS Number: CAS 185376-97-0
  TTD Drug ID: DMHDYBN

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2C receptor (HTR2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[3]
Lorcaserin	DMG6OYJ	Obesity	5B81	Approved	[4]
Tramadol	DMRQD04	Osteoarthritis	FA00-FA05	Approved	[5]
Mirtazapine	DML53ZJ	Depression	6A70-6A7Z	Approved	[6]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[7]
Methysergide	DM1EF73	Migraine	8A80	Approved	[8]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[9]
M100907	DM7ZFBA	Sleep-wake disorder	7A00-7B2Z	Phase 3	[10]
SR46349B	DM1ODMR	Primary insomnia	7A00	Phase 3	[11]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2C receptor (HTR2C)	TTWJBZ5	5HT2C_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 187).
• [2] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [3] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [4] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [5] The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents.
• [6] Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57.
• [7] Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60.
• [8] Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8.
• [9] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [10] Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12.
• [11] SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41.
• [12] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.